A Nature Communications study reported that a genetically engineered, ROS‑tolerant probiotic remodeled the gut microbiota and host metabolism to reverse key features of type 2 diabetes in male mice. The team used synthetic biology to enhance probiotic survival in oxidative gut environments and measured improvements in glucose tolerance, insulin sensitivity, and metabolic biomarkers. The work demonstrates a proof‑of‑concept for microbe‑based metabolic interventions; translation will require safety, dosing, and mechanistic studies in larger animal models before human trials.